Anixa Biosciences (NASDAQ: ANIX) CEO adds 21,000 shares

Rhea-AI Filing Summary

Anixa Biosciences Chief Executive Officer Amit Kumar reported an open-market purchase of 21,000 shares of Common Stock at $2.50 per share. This transaction increased his direct ownership to 630,812 shares following the trade. The filing reflects a single buy transaction with no accompanying sales or derivative exercises.

Insider Trade Summary

Net Buyer: 21,000 shares ($52,500)

Net Buy 1 txn

Insider KUMAR AMIT

Role Chief Executive Officer

Bought 21,000 shs ($53K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	21,000	$2.50	$53K

Holdings After Transaction: Common Stock — 630,812 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 21,000 shares Purchase price: $2.50 per share Shares owned after: 630,812 shares +1 more

4 metrics

Shares purchased 21,000 shares Open-market buy of Common Stock

Purchase price $2.50 per share Price for the 21,000-share open-market purchase

Shares owned after 630,812 shares Direct holdings following the reported transaction

Net share change 21,000 shares Net-buy shares from transaction summary

Key Terms

open-market purchase, Common Stock, Form 4

3 terms

open-market purchase financial

"reported an open-market purchase of 21,000 shares of Common Stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"open-market purchase of 21,000 shares of Common Stock at $2.50 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"was the only transaction disclosed in this Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUMAR AMIT

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		P		21,000	A	$2.5	630,812	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amit Kumar	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Anixa Biosciences (ANIX) report?

Anixa Biosciences reported that CEO Amit Kumar purchased 21,000 shares of Common Stock. The open-market buy was executed at $2.50 per share and was the only transaction disclosed in this Form 4.

At what price did the Anixa Biosciences CEO buy ANIX shares?

The CEO bought Anixa Biosciences Common Stock at $2.50 per share. This price applies to all 21,000 shares purchased in the reported open-market transaction on the stated transaction date.

How many Anixa Biosciences shares does the CEO hold after this trade?

Following the transaction, CEO Amit Kumar directly owns 630,812 Anixa Biosciences shares. This total reflects his position after adding the newly purchased 21,000 shares disclosed in the Form 4 filing.

Was the Anixa Biosciences CEO’s transaction a buy or a sell?

The transaction was a buy, specifically an open-market purchase of Common Stock. The Form 4 shows one purchase transaction and no reported sales, gifts, or derivative exercises associated with this event.

Does this Anixa Biosciences Form 4 include any derivative securities?

No derivative securities are shown in this Form 4. The filing reports only a non-derivative transaction, where the CEO purchased Common Stock directly, with no options or other derivatives listed in the derivative summary.